| abstract |
The present invention relates to inhibitors of the Wnt signalling pathways of general formula (I) wherein L A represents *CH 2 ** or *Δ**; wherein indicates the point of attachment to the carbonyl group, and ** indicates the point of attachment to R 1 ; L B represents *N(H)-C(=O)** or *C(=O)-N(H)**; wherein * indicates the point of attachment to R 2 , and ** indicates the point of attachment to the phenyl group; R 1 represents a group selected from: (AA); wherein * indicates the point of attachment to L A , R 2 represents: (BB) wherein * indicates the point of attachment to R 3 , and ** indicates the point of attachment to L B R 3 represents a group selected from: (CC); wherein * indicates the point of attachment to R 2 ; R 4 and R 5 represent a hydrogen atom; and R 6 represents a halogen atom or group selected from: -CH 3 , -O-CH 3 , -O-CHF 2 , -O-CF 3 , and -O-cyclopropyl; to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular, of a hyper-proliferative disorder, as a sole agent or in combination with other active ingredients. |